1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022;36:1703–1719.
2. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
4. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28:241–247.
6. Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid 2022;1:2200008.
7. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456–1465.
8. Aguirre LE, Al Ali N, Sallman DA, et al. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia 2023;37:1530–1539.
9. Kewan T, Bahaj W, Durmaz A, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes. Blood 2023;141:1768–1772.
10. Sauta E, Robin M, Bersanelli M, et al. Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes. J Clin Oncol 2023;41:2827–2842.
11. Yang T, Jiang B, Luo Y, et al. Comparison of the prognostic predictive value of molecular international prognostic scoring system and revised international prognostic scoring system in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms. Am J Hematol 2023;98:E391–E394.
12. Bejar R. How can we incorporate molecular data into the IPSS? Best Pract Res Clin Haematol 2022;35:101410.
13. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140:1200–1228.
15. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382:140–151.
19. Platzbecker U, Della Porta MG, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lowerrisk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet 2023;402:373–385.
21. Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med 2020;26:1549–1556.
22. Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2022;139:2347–2354.
24. da Silva-Coelho P, Kroeze LI, Yoshida K, et al. Clonal evolution in myelodysplastic syndromes. Nat Commun 2017;8:15099.
25. Cogle CR, Saki N, Khodadi E, Li J, Shahjahani M, Azizidoost S. Bone marrow niche in the myelodysplastic syndromes. Leuk Res 2015;39:1020–1027.